R-CHOP联合大剂量甲氨蝶呤及鞘内化疗治疗新诊断血管内大B细胞淋巴瘤的II期试验
PRIMEUR-IVL是一项多中心单臂II期试验,纳入37例无中枢神经系统受累的新诊断血管内大B细胞淋巴瘤患者,评估R-CHOP联合大剂量甲氨蝶呤及鞘内化疗的疗效与安全性。主要终点2年无进展生存率为76%(95%CI 58-87),最常见3-4级不良事件为中性粒细胞减少和白细胞减少(38例,100%),未发生治疗相关死亡。
要点
- 2年无进展生存率达76%(95%CI 58-87)。
- 3-4级中性粒细胞减少和白细胞减少见于全部38例(100%)。
- 方案安全性可接受,无治疗相关死亡。
核心结论
- R-CHOP联合利妥昔单抗、大剂量甲氨蝶呤及鞘内化疗对诊断时无明显中枢神经系统受累的血管内大B细胞淋巴瘤安全且有效。
研究设计与样本
- 多中心、单臂、II期试验,在日本22家医院开展。
- 纳入38例患者,37例符合条件,1例因睾丸淋巴瘤病史被排除。
- 患者年龄20-79岁,ECOG体能状态0-3分,诊断时无明确中枢神经系统受累。
- 主要终点为2年无进展生存率。
主要发现
- 2年无进展生存率为76%(95%CI 58-87)。
- 最常见的3-4级不良事件为中性粒细胞减少和白细胞减少,38例(100%)均报告。
- 严重不良事件包括低钾血症、发热性中性粒细胞减少伴低血压、高血压和脑出血,各报告1例(3%)。
- 方案治疗期间无治疗相关死亡。
临床怎么用
- 该方案可作为无中枢神经系统受累的新诊断血管内大B细胞淋巴瘤的治疗选择。
- 治疗期间需密切监测血液学毒性及严重不良事件。
局限性
- 单臂设计,无随机对照。
- 样本量较小(37例符合条件)。
- 随访时间有限,长期随访仍在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intravascular large B-cell lymphoma (IVLBCL) is a rare disease for which there is no available standard treatment. We aimed to ascertain the safety and activity of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) with high-dose methotrexate and intrathecal chemotherapy as CNS-oriented therapy for patients with previously untreated IVLBCL. METHODS: PRIMEUR-IVL is a multicentre, single-arm, phase 2 trial at 22 hospitals in Japan. Eligible patients had untreated histologically confirmed IVLBCL, were aged 20-79 years, had an Eastern Cooperative Group performance status of 0-3, and had no apparent CNS involvement at diagnosis. Patients received three cycles of R-CHOP (rituximab 375 mg/m2 intravenously on day 1 [except cycle one, which was on day 8]; cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 [maximum 2·0 mg] intravenously on day 1 of cycle one and day 2 of cycles two and three; and prednisolone 100 mg/day orally on days 1-5 of cycle one and days 2-6 of cycles two and three) followed by two cycles of rituximab with high-dose methotrexate (3·5 g/m2 intravenously on day 2 of cycles four and five) every 2 weeks and three additional cycles of R-CHOP. Intrathecal chemotherapy (methotrexate 15 mg, cytarabine 40 mg, and prednisolone 10 mg) was administered four times during the R-CHOP phase. The primary endpoint was 2-year progression-free survival. Efficacy analyses were done in all enrolled patients; safety analyses were done in all enrolled and treated patients. The trial is registered in the UMIN Clinical Trials Registry (UMIN000005707) and the Japan Registry of Clinical Trials (jRCTs041180165); the trial is ongoing for long-term follow-up. FINDINGS: Between June 16, 2011, and July 21, 2016, 38 patients were enrolled, of whom 37 were eligible; one patient was excluded because of a history of testicular lymphoma. Median follow-up was 3·9 years (IQR 2·5-5·5). 2-year progression-free survival was 76% (95% CI 58-87). The most frequent adverse events of grade 3-4 were neutropenia and leucocytopenia, which were reported in all 38 (100%) patients. Serious adverse events were hypokalaemia, febrile neutropenia with hypotension, hypertension, and intracerebral haemorrhage (reported in one [3%] patient each). No treatment-related deaths occurred during protocol treatment. INTERPRETATION: R-CHOP combined with rituximab and high-dose methotrexate plus intrathecal chemotherapy is a safe and active treatment for patients with IVLBCL without apparent CNS involvement at diagnosis, and this regimen warrants future investigation. FUNDING: The Japan Agency for Medical Research and Development, the Center for Supporting Hematology-Oncology Trials, and the National Cancer Center.
引用
- Shimada K, Yamaguchi M, Atsuta Y, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020. PMID: 32171071. doi:10.1016/S1470-2045(20)30059-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。